In the comparison of Wegovy vs Zepbound, Zepbound has produced larger average weight loss in trials, but it is not automatically the right choice for every patient. Wegovy is semaglutide, a GLP-1 receptor agonist. Zepbound is tirzepatide, which acts on two receptors, GLP-1 and GIP. Both are FDA approved for weight management, and the better drug is the one that fits a specific person's tolerance, access, and metabolic picture.
This guide compares the two on trial results, side effects, and cost, and explains how a clinician actually decides.
- Tirzepatide (Zepbound) produced more average weight loss in trials than semaglutide (Wegovy), but trial averages describe populations, not individuals.
- Zepbound's dual GLP-1/GIP action is the mechanistic reason it tends to outperform Wegovy on average.
- Both drugs share the same core side effects, and slow titration is the biggest lever for tolerability with either one.
- Compounded versions are no longer the standard of care now that the 2021–2025 FDA shortage has resolved; branded Wegovy or Zepbound is the appropriate path.
- Switching between the two is common for tolerance, results, or access reasons, but requires restarting titration on the new agent.
- Both medications work best inside a supervised plan pairing medication with protein, resistance training, and a maintenance strategy.
How the two medications differ
Wegovy (semaglutide) mimics a single gut hormone that reduces appetite and slows gastric emptying. Zepbound (tirzepatide) activates GLP-1 and GIP receptors at once, which appears to compound the metabolic effect. That dual action is the mechanistic reason tirzepatide tends to produce more weight loss on average.
That does not make it the default. The second receptor also shapes side effects and tolerance, and the right tool depends on how a given patient responds. Our guide on tirzepatide versus semaglutide covers the mechanism in more depth.
What the trials show
The headline numbers come from large randomized trials.
Trial Results at a Glance
Averages from pivotal randomized trials
| Drug | Trial | Average Weight Loss | Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | STEP 1 | roughly 15 percent | 68 weeks |
| Tirzepatide (Zepbound) | SURMOUNT-1 | up to about 21 percent (highest dose) | 72 weeks |
On paper, tirzepatide leads. In practice the gap narrows once dose tolerance, adherence, and the individual response in the first eight weeks are accounted for. Trial averages describe populations, not the person in front of the clinician, and plenty of people reach their goal on semaglutide.
Side effects and tolerance
Both drugs share the same main side effects, which come from how they slow the gut: nausea, constipation, diarrhea, and occasional vomiting, mostly during dose increases. Slow titration is the single biggest lever for tolerability, and it is the same playbook for both medications. Some people tolerate one better than the other, which is itself a reason the choice is individual. For managing these effects, see our guide on GLP-1 side effects and how to manage them.
Without adequate protein, resistance training, and careful titration, rapid weight loss includes lean muscle. The weight that comes off should be mostly fat, and that requires a supervised plan, not just a prescription.
Cost and access
Both are branded medications and are priced accordingly, often near or above 1,000 dollars a month at list price before insurance, coupons, or manufacturer savings. Coverage varies widely by plan and by indication. In practice, which drug a patient can actually get and afford often decides the matter as much as the trial data does.
This is where the regulatory ground matters. Compounded semaglutide and tirzepatide were available during the 2021 to 2025 FDA shortage, but the shortage has resolved and compounding is now restricted. The standard of care is branded, FDA-approved Wegovy or Zepbound. The right response is to pursue prior authorization and manufacturer savings, not to substitute compounded drug to cut cost. Our guide on compounded versus branded GLP-1 explains what changed.
How a clinician chooses
The decision weighs several inputs: how much weight loss the patient needs, their tolerance and side-effect history, insurance coverage and access, existing insulin resistance, and how they respond in the first two months. At GoodLife Health, a clinician reads the full metabolic panel before prescribing, then titrates slowly and adjusts based on weekly check-ins rather than committing to one agent on day one. Medical weight loss sits in the 399 dollar a month tier, with medication billed separately by the pharmacy and no markup from GoodLife.
Can you switch between Wegovy and Zepbound?
Switching between the two is common and clinically reasonable, and there are a few situations where it makes sense.
The most frequent reason is tolerance. If someone has persistent nausea or other side effects on one agent despite slow titration, moving to the other can improve how they feel, because the two drugs act on the receptors differently. A switch is also driven by results. If weight loss stalls well short of the goal on a maximized, well-tolerated dose of one medication, the other may produce further progress.
Access is the third driver, and often the most practical. Insurance coverage, manufacturer savings, and supply all shift over time, and the medication a patient can actually get and afford sometimes decides the matter more than the trial data does. A clinician who is paid a flat fee, rather than a margin on the drug, can make that call on clinical and access grounds without a financial thumb on the scale.
Switching is not a casual flip. Dosing does not translate one-to-one between the two medications, so a switch means restarting titration at an appropriate dose for the new agent and climbing slowly again. Expect the early side effects to return briefly during that ramp, just as they did the first time, and expect a short period of adjustment before the new agent settles.
The choice between Wegovy and Zepbound, and the decision to switch, is one input into that plan, not the plan itself.
The larger point is that neither drug is a finish line. Both work best inside a supervised plan that pairs the medication with protein, resistance training, and a maintenance strategy, so the weight that comes off is mostly fat and stays off. Read against your own labs, tolerance, and access, the right answer is usually clearer than the trial averages alone suggest.
Frequently Asked Questions
Is Zepbound better than Wegovy for weight loss?
On average, tirzepatide (Zepbound) produced more weight loss in trials, up to about 21 percent in SURMOUNT-1 versus roughly 15 percent for semaglutide (Wegovy) in STEP 1. But the best drug is the one a given patient tolerates and can access, and many people reach their goal on Wegovy.
What is the difference between Wegovy and Zepbound?
Wegovy is semaglutide, which acts on the GLP-1 receptor. Zepbound is tirzepatide, which acts on both the GLP-1 and GIP receptors. The dual action is why tirzepatide tends to produce more weight loss, but it also shapes tolerance.
Do Wegovy and Zepbound have the same side effects?
Largely yes. Both cause nausea, constipation, diarrhea, and sometimes vomiting, mostly during dose increases. Slow titration improves tolerability for both, and some people tolerate one better than the other.
How much do Wegovy and Zepbound cost?
Both are branded medications, often priced near or above 1,000 dollars a month at list before insurance or manufacturer savings. Coverage varies by plan, so access and affordability often influence which one a patient uses.
Does GoodLife prescribe Wegovy and Zepbound?
Yes, when clinically appropriate. Medical weight loss is part of the 399 dollar a month tier. A clinician reads your metabolic panel, chooses the agent, and supervises titration, with medication billed separately by the pharmacy.
Related Reading
- Best Medical Weight Loss Programs: The Clinically Honest Guide for 2026
- Compounded vs Branded GLP-1: What Changed in 2025
- GLP-1 Side Effects: What to Expect and How to Manage Them
- GLP-1 Weight Loss Plateau: Why It Happens and How to Break It
- GLP-1 Prior Authorization for Weight Loss Medication: A Step-by-Step Guide
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022.
This article is informational only and is not medical advice. GoodLife Health is a direct primary care telehealth membership, not a pharmacy or compounder, and does not sell medication. Individual results vary. Consult a licensed clinician.